Vanderbilt University Medical Center, Nashville, TN, USA.
University of Maryland School of Medicine, Baltimore, MD, USA.
Drug Des Devel Ther. 2023 Jan 31;17:273-282. doi: 10.2147/DDDT.S379446. eCollection 2023.
This article will review risankizumab, a monoclonal antibody targeting interleukin 23 (IL-23) for the treatment of moderate-to-severe Crohn's disease. The article will detail the mechanism of action and dosing strategies. Efficacy in induction and maintenances will be reviewed from available clinical trials as well as an evaluation of safety of the medication for use in Crohn's disease and other immune mediated diseases. Finally, a discussion of when to use this medication for treatment in Crohn's disease as well as how to monitor patients after medication initiation will be discussed.
这篇文章将回顾 risankizumab，一种针对白细胞介素 23（IL-23）的单克隆抗体，用于治疗中重度克罗恩病。本文将详细介绍其作用机制和给药策略。将从现有临床试验中回顾该药物在诱导和维持缓解方面的疗效，并评估该药在克罗恩病和其他免疫介导性疾病中的安全性。最后，将讨论何时在克罗恩病中使用该药治疗以及在开始用药后如何监测患者。
